Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study.
Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study.
复制标题
DOI：
10.1177/1352458511398054
复制
发表时间：
2011-06
期刊：
影响因子：
--
通讯作者：
Fabry Z
中科院分区：
文献类型：
--
作者：
Fleming JO;Isaak A;Lee JE;Luzzio CC;Carrithers MD;Cook TD;Field AS;Boland J;Fabry Z
基于卫生学假说的益生菌治疗策略，如给予非致病性蠕虫猪毛线虫（Trichuris suis， TSO）的卵，已被证明对自身免疫性炎症性肠病是安全有效的。为了研究TSO在第二种自身免疫性疾病多发性硬化症（MS）中的安全性和效果，我们进行了1期蠕虫诱导免疫调节治疗（HINT 1）研究。在基线与治疗对照的探索性试验中，5名新诊断的、未经治疗的复发-缓解型多发性硬化症（RRMS）患者每2周口服2500 TSO，持续3个月。新发钆增强磁共振成像（MRI）病变（n-Gd+）的平均数量从基线时的6.6个下降到TSO给药结束时的2.0个，TSO停药2个月后，n-Gd+的平均数量上升到5.8个。未观察到明显的不良反应。在初步免疫学调查中，5名受试者中有4名血清中细胞因子IL-4和IL-10水平升高。在这种新型益生菌在RRMS中的首次人体研究中，TSO耐受性良好，并且在探索性MRI和免疫学评估中观察到有利的趋势。需要进一步的研究来充分探索这种免疫调节治疗的安全性、效果和作用机制。
Probiotic treatment strategy based on the hygiene hypothesis, such as administration of ova from the non-pathogenic helminth, Trichuris suis, (TSO) has proven safe and effective in autoimmune inflammatory bowel disease. To study the safety and effects of TSO in a second autoimmune disease, multiple sclerosis (MS), we conducted the phase 1 Helminth-induced Immunomodulatory Therapy (HINT 1) study. Five subjects with newly diagnosed, treatment-naive relapsing–remitting multiple sclerosis (RRMS) were given 2500 TSO orally every 2 weeks for 3 months in a baseline versus treatment control exploratory trial. The mean number of new gadolinium-enhancing magnetic resonance imaging (MRI) lesions (n-Gd+) fell from 6.6 at baseline to 2.0 at the end of TSO administration, and 2 months after TSO was discontinued, the mean number of n-Gd+ rose to 5.8. No significant adverse effects were observed. In preliminary immunological investigations, increases in the serum level of the cytokines IL-4 and IL-10 were noted in four of the five subjects. TSO was well tolerated in the first human study of this novel probiotic in RRMS, and favorable trends were observed in exploratory MRI and immunological assessments. Further investigations will be required to fully explore the safety, effects, and mechanism of action of this immunomodulatory treatment.
登录
查看更多内容
影响因子：
9.1
作者：
Costantino, Cristina Maria;Baecher-Allan, Clare;Hafler, David A.
通讯作者：
Hafler, David A.
影响因子：
6.4
作者：
Grogan, JL;Kremsner, PG;Yazdanbakhsh, M
通讯作者：
Yazdanbakhsh, M
DOI：
10.1111/j.1365-2222.2009.03433.x
发表时间：
2010-02
期刊：
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
影响因子：
--
作者：
Feary JR;Venn AJ;Mortimer K;Brown AP;Hooi D;Falcone FH;Pritchard DI;Britton JR
通讯作者：
Britton JR
DOI：
10.1084/jem.20091903
发表时间：
2009-09-28
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Maizels RM;Pearce EJ;Artis D;Yazdanbakhsh M;Wynn TA
通讯作者：
Wynn TA
影响因子：
100.3
作者：
Harnett, William;Harnett, Margaret M.
通讯作者：
Harnett, Margaret M.